Glioblastoma Multiforme Gbm Market

DelveInsight’s ‘Glioblastoma Multiforme (GBM) Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Glioblastoma Multiforme (GBM), historical and forecasted epidemiology as well as the Glioblastoma Multiforme (GBM) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Glioblastoma Multiforme (GBM) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Glioblastoma Multiforme (GBM) market size from 2017 to 2030. The report also covers current Glioblastoma Multiforme (GBM) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

Glioblastoma Multiforme (GBM) Disease Understanding and Treatment Algorithm

Glioblastoma Multiforme (GBM) Overview

Glioblastoma (GBM) is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed. Somatic evolution promotes the progression of cancer in which the genome of the cancer cell is being deviated from that of the healthy cell due the accumulation of mutations. There is a remarkable development in GBM because it occurs via a complex network of various different molecular and genetic aberrations, which leads to significant changes in major signaling pathways. GBMs, as they extensively disperse throughout the parenchyma, making maximal surgical resection unattainable and having high level of vascularization, are lethal in nature.


GBM is often located in a region of the forebrain known as the cerebrum, which controls some of the most advanced process such as speech and emotions. While GBM is highly locally invasive (invading normal brain tissue), it rarely spreads to other organs beyond the brain. A highly aggressive, fast-growing cancer and treatment is often limited by the tumor location and the ability of a patient to tolerate surgery. Consequently, it is a particularly difficult cancer to treat.


Glioma is considered as the general term which is used to describe the primary brain tumors, and it is also classified to their presumed cell of origin accordingly. The classification includes astrocytic tumors (astrocytoma, anaplastic astrocytoma and glioblastoma), oligodendrogliomas, ependymomas, and mixed gliomas. Gliomas are classified into grade I TO IV on the basis of malignancy that is determined by the histopathalogical criteria.


Although the location of GBM is commonly found in the supratentorial region (frontal, temporal, parietal, and occipital lobes), it is rarely located in the cerebellum part. Investigation of genetic and environmental factors of GBM have been done. Prior radiography, decreased susceptibility to allergy, immune factors and immune genes, as well as some nucleotide polymorphisms detected by genomic analysis are all included in the risk factors of the respective disease. The histological classification and tumor grading is a critical step for GBM diagnosis and prognosis.


GBM is a grade IV glioma according to the WHO 2007 classification and is the most common and lethal primary malignancy of the central nervous system. Despite multidisciplinary treatments such as surgery, chemotherapy, and radiotherapy, the median survival time for patients with GBM is only 14.6 months. Due to its high degree of invasiveness, radical tumor resection is not curative. From various experimental evidences it is explained that GBM contains a subpopulation of highly tumorigenic cells (GBM stem cells) from which recurrent GBM is thought to derive, and that GBM has the capacity to differentiate into multiple lineages of tumor genesis.


 GBMs can be classified into primary and secondary GBMs:

  • Primary GBM occurs de novo without evidence of a less malignant precursor
  • Secondary GBM develops from initially low-grade diffuse astrocytoma (WHO grade II diffuse astrocytoma) or anaplastic astrocytoma (Grade III). 

Glioblastoma Multiforme (GBM) Diagnosis

A patient with any neurological symptoms will first be given a physical exam that includes neurologic function tests (reflexes, muscle strength, eye and mouth movement, coordination and alertness). If a tumor is suspected, the patient will have imaging tests so that doctors can look into the brain for any abnormality. A neurological exam alone is not sufficient to make a glioblastoma diagnosis, but the results will indicate whether additional testing is needed. If the results of a neurological exam suggest a potential glioblastoma diagnosis, imaging tests may then be used to produce an in-depth picture of the brain. Procedures that can be used for this purpose include:

  • Neurological Exams
  • Angiograms
  • Magnetic resonance imaging (MRI) and computerized Tomography (CT)
  • Perfusion MRI
  • MR spectroscopy
  • Histological Diagnosis
  • Surgical Biopsy 

Glioblastoma Multiforme (GBM) Treatment

Treatment for GBM usually includes a combination of surgery, chemotherapy, radiation, or stereotactic radiosurgery. Surgery is usually one of the most important aspects of treatment, although rarely used alone. Since glioblastomas develop very rapidly, they are often difficult to remove in their entirety. Therefore, surgery is performed to achieve a maximum safe resection - removing as much of the tumor as possible while preserving the patient’s brain function and sparing healthy tissues. Residual cancer cells can be targeted with additional treatments, such as chemotherapy or radiation therapy, after surgery. Radiation therapy and chemotherapy usually follow surgery once the diagnosis or name of the tumor is determined. These treatments are called adjuvant treatments. Because this multispecialty approach can cause several side effects, steroids are often provided as another essential part of glioblastoma treatment,

used to help alleviate the side effects of other therapies.


The mainstay of treatment for Glioblastoma is surgery, followed by radiation and chemotherapy. Glioblastoma surgery is performed to achieve a “maximum safe resection,” or removing as much of the tumor as possible without causing lasting neurological damage.


Glioblastoma surgery options majorly include: Craniotomy , Awake craniotomy, Debulking surgery, Skull base surgery, Visualase and Kyphoplasty. In most cases, surgeons perform a craniotomy, opening the skull to reach the tumor site. This is done frequently with computer-assisted image-guidance and at times using intra-operative mapping techniques to determine the locations of the motor, sensory and speech/language cortex.


Currently, the first- and second-line treatment of GBM is more prevalent throughout the 7MM. The first-line treatment involves drug therapy following surgery, which includes Temozolomide + Radiation Therapy and Temozolomide Monotherapy. While the second-line treatment for GBM includes Bevacizumab Monotherapy, Bevacizumab Combination Therapy, Temozolomide (Both as Combination and Monotherapy), and Other Systemic Therapies (Concomitant and Adjuvant).

Glioblastoma Multiforme (GBM) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Population of Glioblastoma Multiforme (GBM), Gender-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Type-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Age-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Diagnosed Incident Population based on Primary Site of Glioblastoma Multiforme (GBM) Tumour and Diagnosed Incident Population based on Histologic Classification of Glioblastoma Multiforme (GBM) Tumor in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Key Findings

This section provides glimpse of the Glioblastoma Multiforme (GBM) epidemiology in the 7MM.

  • The total diagnosed incident population of Glioblastoma Multiforme in the 7 major markets was estimated to be 28,259 in 2017. In case of Glioblastoma Multiforme patients in the United States, the diagnosed cases were 14,666 in 2017.
  • The total diagnosed incident cases of Glioblastoma Multiforme patients were found to be maximum in males as compared to females in the 7 MM during the study period of 2017–2030.
  • In the EU5 countries, the diagnosed incident population of Glioblastoma Multiforme was found to be maximum in Germany with 2,876 cases followed by France with 2,683 cases in 2017. While, Spain accounted for the lowest diagnosed incident population of 1,403 in 2017.
  • As per Delvelnsight’s analysis, Japan had 1,899 diagnosed incident cases of Glioblastoma Multiforme in 2017.

Country Wise- Glioblastoma Multiforme (GBM) Epidemiology

The epidemiology segment also provides the Glioblastoma Multiforme (GBM) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Glioblastoma Multiforme (GBM) Drug Chapters

The drug chapter segment of the Glioblastoma Multiforme (GBM) report encloses the detailed analysis of Glioblastoma Multiforme (GBM) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Glioblastoma Multiforme (GBM) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Glioblastoma Multiforme (GBM) Marketed Drugs

Avastin: Genentech

Avastin (Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody, which acts as angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). Bevacizumab binds to the vascular endothelial growth factor (VEGF) with its receptor VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. This helps in reducing the activity of VEGF and regressing the vascularization of tumors, which normalizes the tumor vasculature and inhibits the formation of new tumor vasculature, thereby preventing the tumor growth. VEGF is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer. Bevacizumab was the first clinically available angiogenesis inhibitor in the United States. In September 2014, Genentech reclassified the drug under “Specialty drugs,” only to be available through specialty pharmacies (under FDA’s Risk Evaluation and Mitigation Strategy (REMS) program).


Avastin is indicated for the treatment of glioblastoma with progressive disease in adult patients following prior therapy as a single agent. The effectiveness of Avastin in glioblastoma is based on an improvement in objective response rate, wherein no data demonstrate any improvement in disease-related symptoms or increased survival with Avastin.

Product details in the report…

Temodar/Temodal: Merck

The active pharmaceutical ingredient in Temodar/Temodal, is an imidazotetrazine derivative of the alkylating agent dacarbazine.


Temozolomide is used for the treatment of several brain cancer forms, e.g., as a second-line treatment for astrocytoma and as a first-line treatment for glioblastoma. The therapeutic benefit of temozolomide is due to its ability to alkylate/methylate DNA. This alkylation/methylation destroys the DNA and triggers the death of the tumor cells. Temozolomide targets selectively tumoral tissues; it has an anti-neoplastic effect; it has minimum influence on adjacent brain tissues; it has no severe systemic toxicity, and it is eliminated rapidly.


Temodar/Temodal was initially commercialized by Merck in the different countries, whereas Baxter Oncology was responsible for the manufacture of Temodar injection. However, due to patent expiry, the market holds the generic version of the drug. Recently, the gel formulation of Temozolomide has also been approved by Double Bond Pharmaceuticals.

Product details in the report…

Glioblastoma Multiforme (GBM) Emerging Drugs

Ofranergene obadenovec (VB-111): VBL Therapeutics

Product details in the report…

Trans Sodium Crocetinate: Diffusion Pharmaceuticals

Product details in the report…

Regorafenib: Bayer

Product details in the report…

Durvalumab (MEDI4736): MedImmune

Product details in the report…

Tasadenoturev (DNX-2401): DNAtrix

Product details in the report…

ONC201: Oncoceutics

Product details in the report…

Selinexor (KPT-330): Karyopharm Therapeutics

Product details in the report…

Paxalisib (GDC-0084): Kazia Therapeutics

Product details in the report…

AV-GBM-1: Aivita Biomedical

Product details in the report…

MDNA55: Medicenna Therapeutics

Product details in the report…

Glioblastoma Multiforme (GBM) Market Outlook

Glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Unfortunately, there is no cure for glioblastoma.


Glioblastoma treatment is quite challenging as some cells may respond well to certain therapies, while others may not be affected at all. Because of this, the treatment plan for glioblastoma may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by the additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery. Treatment is palliative and may include surgery, radiation therapy and/or chemotherapy. The best treatment options for each person depending on many factors like the size and location of the tumor; the extent to which the tumor has grown into the surrounding normal brain tissues; and the affected person’s age and overall health.


In April 2005, the FDA approved a new indication for Temodar capsules (temozolomide) for concurrent use with radiotherapy for the treatment of adults with newly diagnosed GBM and as maintenance therapy after radiotherapy. Inaddition, in December 2017, the FDA granted full approval of bevacizumab (Avastin) for the treatment of adults with recurrent glioblastoma that has progressed following prior therapy. In case of European and Japanese market, only Temodar has been approved by the EMA and MHLW respectively, for the treatment of patients with GBM.


Glioblastoma Multiforme pipeline is robust and possesses multiple potential drugs in late and mid-stage developments, which is yet to be launched. The pipeline involves drugs with a varied mechanism of action along with different routes of administration, ranging from oral, intravenous, intratumoral, subcutaneous, etc. It is interesting to note that the emerging market of GBM includes budding gene therapy, i.e., Ofranergene obadenovec (VB-111) by VBL Therapeutics, followed by four vaccine/immunotherapy candidates such as VBI-1901, AV-GBM-1 and ITI-1000 (pp65 DC Vaccine), Tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively.


The potential candidates with promising results in late- or phase III stage of clinical development include Ofranergene obadenovec (VB-111; VBL Therapeutics), Trans Sodium Crocetinate (Diffusion Pharmaceuticals), and Regorafenib (Bayer).

Key Findings

This section includes a glimpse of the Glioblastoma Multiforme (GBM) 7MM market.

  • The market size of GBM in the seven major markets was estimated to be USD 1,005 Million in 2017.
  • The United States accounts for the largest market size of GBM throughout the study period of 2017–2030, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan, which was estimated to be USD 629 Million in 2017.
  • Among the EU5 countries, Germany had the highest market size with USD 73 Million in 2017, while Spain had the lowest market size with USD 35 Million.
  • Japan accounted for the second highest market size in the 7 MM during the forecast period of 2020–2030, which was estimated to be USD 82 Million in 2017.


The United States Market Outlook

This section provides the total Glioblastoma Multiforme (GBM) market size and market size by therapies in the United States.


EU-5 Market Outlook

The total aspregillosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total Glioblastoma Multiforme (GBM) market size and market size by therapies in Japan are provided.


Glioblastoma Multiforme (GBM) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Glioblastoma Multiforme (GBM) market or expected to get launched in the market during the study period 2017–2030. The analysis covers Glioblastoma Multiforme (GBM) market uptake by drugs; patient uptake by therapies; and sales of each drug.  


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Glioblastoma Multiforme (GBM) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Glioblastoma Multiforme (GBM) emerging therapies.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Glioblastoma Multiforme (GBM) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Glioblastoma Multiforme (GBM), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Glioblastoma Multiforme (GBM) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Glioblastoma Multiforme (GBM) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Glioblastoma Multiforme (GBM) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Glioblastoma Multiforme (GBM) market.

Report Highlights

  • In the coming years, Glioblastoma Multiforme (GBM) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Glioblastoma Multiforme (GBM) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Delvelnsight has analysed type-specific data of GBM according to which there are two main types of Glioblasoma: Primary (de novo) and Secondary Glioblastoma, where the majority of cases (>90%) are primary glioblastomas that develop rapidly de novo, without clinical or histological evidence of a less malignant precursor lesion.
  • Diagnosed incidence according to histological classification of Glioblastoma Multiforme tumor was also assessed, which suggests that the conventional GBM type is more prevalent than giant cell GBM (GC-GBM), and gliosarcoma (GS).
  • In addition, gener-specific incidence of Glioblastoma Multiforme was also assessed. As per the analysis, GBm is more prevalent in males than in females.
  • The epidemiology segmentation also encompasses diagnosed incident population according to primary site of glioblastoma. As per the DelveInsight estimates, it has been found that the primary site of GBM included maximum cases at parietal site, while minimum number of cases were found in unknown and other sites. This trend is clearly evident across all the 7MM countries for the study period 2017–2030.
  • The report also encompasses another major segment, i.e., Age-specific Diagnosed Incident Population of Glioblstoma Multiforme (GBM), wherein various age groups have been considered, such as <18, 18–34, 35–64, 65–74 and 75+. It has been found that GBM incidence increases with age peaking at 75–84 years and drops after 85 years.
  • Expected Launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of GBM. The market is expected to witness a significant positive shift owing to the positive outcomes of the several products during the developmental stage by key players such as Bayer, Diffusion Pharmaceuticals, VBL Therapeutics, AstraZeneca, DNAtrix, DelMar Pharmaceuticals, Oncoceutics, KaryoPharma, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Immunomic Therapeutics and Inovio Pharmaceuticals.

Glioblastoma Multiforme (GBM) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Glioblastoma Multiforme (GBM) Pipeline Analysis
  • Glioblastoma Multiforme (GBM) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Glioblastoma Multiforme (GBM) Report Key Strengths

  • Eleven Years Forecast
  • 7MM Coverage
  • Glioblastoma Multiforme (GBM) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Glioblastoma Multiforme (GBM) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Glioblastoma Multiforme (GBM) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Glioblastoma Multiforme (GBM) total market size as well as market size by therapies across the 7MM during the forecast period (2020–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Glioblastoma Multiforme (GBM) market size during the forecast period (2020–2030)?
  • At what CAGR, the Glioblastoma Multiforme (GBM) market is expected to grow at the 7MM level during the forecast period (2020–2030)?
  • What would be the Glioblastoma Multiforme (GBM) market outlook across the 7MM during the forecast period (2020–2030)?
  • What would be the Glioblastoma Multiforme (GBM) market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Glioblastoma Multiforme (GBM)?
  • What is the historical Glioblastoma Multiforme (GBM) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Glioblastoma Multiforme (GBM) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Glioblastoma Multiforme (GBM)?
  • Out of the above-mentioned countries, which country would have the highest incident population of Glioblastoma Multiforme (GBM) during the forecast period (2020–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Glioblastoma Multiforme (GBM) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Glioblastoma Multiforme (GBM) in the US and Europe?
  • What are the Glioblastoma Multiforme (GBM) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Glioblastoma Multiforme (GBM)?
  • How many therapies are developed by each company for the treatment of Glioblastoma Multiforme (GBM)?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of Glioblastoma Multiforme (GBM)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glioblastoma Multiforme (GBM) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Glioblastoma Multiforme (GBM) and their status?
  • What are the key designations that have been granted for the emerging therapies for Glioblastoma Multiforme (GBM)?
  • What are the 7MM historical and forecasted market of Glioblastoma Multiforme (GBM)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Glioblastoma Multiforme (GBM).
  • To understand the future market competition in the asprgillosis market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Glioblastoma Multiforme (GBM) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Glioblastoma Multiforme (GBM) market.
  • To understand the future market competition in the Glioblastoma Multiforme (GBM) market.

1 Key Insights

2 Glioblastoma Multiforme Market Overview at a Glance

2.1 Market Share (%) Distribution of GBM in 2017

2.2 Market Share (%) Distribution of GBM in 2030

3 Executive Summary of Glioblastoma Multiforme (GBM)

4 Disease Background and Overview: Glioblastoma Multiforme (GBM)

4.1 Introduction

4.2 Classification of Glioblastoma Multiforme

4.3 Glioblastoma Types

4.3.1 Astrocytomas

4.3.2 Ependymomas

4.3.3 Oligodendrogliomas

4.3.4 Mixed gliomas

4.3.5 Optic pathway gliomas

4.4 Symptoms

4.5 Pathophysiology

4.5.1 Macroscopic and Histological Features of GBM

4.5.2 Genetic and Molecular Pathogenesis

4.6 Inheritance of Glioblastoma Multiforme

4.6.1 Genetic Variations of Glioblastoma Multiforme

4.7 Molecular Classification

4.7.1 Specific Molecular Biomarkers

4.8 Diagnosis of Glioblastoma Multiforme

4.8.1 Neurological Exams

4.8.2 Angiograms

4.8.3 Magnetic resonance imaging (MRI) and computerized Tomography (CT)

4.8.4 Perfusion MRI

4.8.5 MR spectroscopy

4.8.6 Histological Diagnosis

4.8.7 Surgical Biopsy

4.9 Glioblastoma in Nut Shell

5 Epidemiology and Patient Population

5.1 Key Findings

5.2 7MM Total Diagnosed Incident Patient Population of Glioblastoma Multiforme

6 Country Wise-Epidemiology of Glioblastoma Multiforme

6.1 United States

6.1.1 Assumptions and Rationale

6.1.2 Total Diagnosed Incident Population of Glioblastoma Multiforme in the United States

6.1.3 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States

6.1.4 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States

6.1.5 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States

6.1.6 Diagnosed Incident Population based on Primary Site of GBM in the United States

6.1.7 Diagnosed Incident Population based on Histologic Classification of GBM Tumor in the United States

6.2 EU5 Countries

6.2.1 Assumptions and Rationale

6.3 Germany

6.3.1 Total Diagnosed Incident Population of Glioblastoma Multiforme in Germany

6.3.2 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany

6.3.3 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany

6.3.4 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany

6.3.5 Diagnosed Incident Population based on Primary Site of GBM in Germany

6.3.6 Diagnosed Incident Population based on Histologic Classification of GBM in Germany

6.4 France

6.4.1 Total Diagnosed Incident Population of Glioblastoma Multiforme in France

6.4.2 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in France

6.4.3 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in France

6.4.4 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in France

6.4.5 Diagnosed Incident Population based on Primary Site of GBM in France

6.4.6 Diagnosed Incident Population based on Histologic Classification of GBM in France

6.5 Italy

6.5.1 Total Diagnosed Incident Population of Glioblastoma Multiforme in Italy

6.5.2 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy

6.5.3 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy

6.5.4 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy

6.5.5 Diagnosed Incident Population based on Primary Site of GBM in Italy

6.5.6 Diagnosed Incident Population based on Histologic Classification of GBM in Italy

6.6 Spain

6.6.1 Total Diagnosed Incident Population of Glioblastoma Multiforme in Spain

6.6.2 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain

6.6.3 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain

6.6.4 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain

6.6.5 Diagnosed Incident Population based on Primary Site of GBM in Spain

6.6.6 Diagnosed Incident Population based on Histologic Classification of GBM in Spain

6.7 United Kingdom

6.7.1 Total Diagnosed Incident Population of Glioblastoma Multiforme in the United Kingdom

6.7.2 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom

6.7.3 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom

6.7.4 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom

6.7.5 Diagnosed Incident Population based on Primary Site of GBM in the United Kingdom

6.7.6 Diagnosed Incident Population based on Histologic Classification of GBM in the United Kingdom

6.8 Japan

6.8.1 Assumptions and Rationale

6.8.2 Total Diagnosed Incident Population of Glioblastoma Multiforme in Japan

6.8.3 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan

6.8.4 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan

6.8.5 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan

6.8.6 Diagnosed Incident Population based on Primary Site of GBM in Japan

6.8.7 Diagnosed Incident Population based on Histologic Classification of GBM in Japan

7 Treatment

7.1 Surgery

7.2 Chemotherapy

7.3 Radiation

7.4 Others

7.4.1 Targeted therapy

7.4.2 Tumor treatment fields (TTF)

7.4.3 Immunotherapy

7.5 Management of Symptoms with Medication

8 Treatment Algorithm

9 The American Society of Clinical Oncology (ASCO) Endorsed American Society for Radiation Oncology (ASTRO) Guideline on Radiation Therapy for Glioblastoma

10 The National Comprehensive Cancer Network (NCCN) Guidelines for Glioblastoma

11 Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions

11.1 Medical Management and Supportive Care

11.2 Standard Therapy

11.3 Surgical Management

11.4 Radiotherapy Considerations

11.5 Recurrent Glioblastoma Scenario

12 SEOM (Medical Oncology Spanish Society) Clinical Guidelines for Diagnosis and Treatment of Glioblastoma

13 Recognized Establishments

14 Unmet Needs

15 Marketed Drugs

1.1 Avastin: Genentech

1.1.1 Drug Description

1.1.2 Regulatory Milestones

1.1.3 Other Development Activities

1.1.4 Safety and Efficacy

1.1.5 Product Profile

1.2 Temodar/Temodal: Merck

1.2.1 Drug Description

1.2.2 Regulatory Milestones

1.2.3 Other Development Activities

1.2.4 Safety and Efficacy

1.2.5 Product Profile

16 Emerging Drugs

16.1 Key Cross Competition

16.2 Other emerging therapies in development

16.3 Ofranergene obadenovec (VB-111): VBL Therapeutics

16.3.1 Product Description

16.3.2 Clinical Development

16.3.3 Safety and Efficacy

16.4 Trans Sodium Crocetinate: Diffusion Pharmaceuticals

16.4.1 Product Description

16.4.2 Clinical Development

16.4.3 Safety and Efficacy

16.5 Regorafenib: Bayer

16.5.1 Product Description

16.5.2 Clinical Development

16.5.3 Safety and Efficacy

16.6 Durvalumab (MEDI4736): MedImmune

16.6.1 Product Description

16.6.2 Clinical Development

16.6.3 Safety and Efficacy

16.7 Tasadenoturev (DNX-2401): DNAtrix

16.7.1 Product Description

16.7.2 Clinical Development

16.7.3 Safety and Efficacy

16.8 ONC201: Oncoceutics

16.8.1 Product Description

16.8.2 Clinical Development

16.8.3 Safety and Efficacy

16.9 Selinexor (KPT-330): Karyopharm Therapeutics

16.9.1 Product Description

16.9.2 Clinical Development

16.9.3 Safety and Efficacy

16.1 VBI-1901: VBI Vaccines

16.10.1 Product Description

16.10.2 Clinical Development

16.10.3 Safety and Efficacy

16.11 Paxalisib (GDC-0084): Kazia Therapeutics

16.11.1 Product Description

16.11.2 Clinical Development

16.11.3 Safety and Efficacy

16.12 AV-GBM-1: Aivita Biomedical

16.12.1 Product Description

16.12.2 Clinical Development

16.12.3 Safety and Efficacy

16.13 MDNA55: Medicenna Therapeutics

16.13.1 Product Description

16.13.2 Clinical Development

16.13.3 Safety and Efficacy

16.14 VAL-083 (Dianhydrogalactitol): DelMar Pharmaceuticals

16.14.1 Product Description

16.14.2 Clinical Development

16.14.3 Safety and Efficacy

16.15 ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics

16.15.1 Product Description

16.15.2 Clinical Development

16.15.3 Safety and Efficacy

16.16 INO-5401+ INO-9012+ Cemiplimab (REGN2810): Inovio Pharmaceuticals

16.16.1 Product Description

16.16.2 Clinical Development

16.16.3 Safety and Efficacy

17 Glioblastoma Multiforme: 7 Major Market Analysis

17.1 Key Findings

17.2 Total Market Size of Glioblastoma Multiforme in the 7 MM

17.3 The United States Market Outlook

17.4 United States Market Size

17.4.1 Total Market size of Glioblastoma Multiforme in the United States

17.4.2 Market Size of Glioblastoma Multiforme by Current Therapies

17.4.3 Market Size of Glioblastoma Multiforme by Emerging Therapies

17.5 EU-5 Countries: Market Outlook

17.6 Germany

17.6.1 Total Market size of Glioblastoma Multiforme in Germany

17.6.2 Market Size of Glioblastoma Multiforme by Current Therapies

17.6.3 Market Size of Glioblastoma Multiforme by Emerging Therapies

17.7 France

17.7.1 Total Market Size of Glioblastoma Multiforme in France

17.7.2 Market Size of Glioblastoma Multiforme by Current Therapies

17.7.3 Market Size of Glioblastoma Multiforme by Emerging Therapies

17.8 Italy

17.8.1 Total Market Size of Glioblastoma Multiforme in Italy

17.8.2 Market Size of Glioblastoma Multiforme by Current Therapies

17.8.3 Market Size of Glioblastoma Multiforme by Emerging Therapies

17.9 Spain

17.9.1 Total Market Size of Glioblastoma Multiforme in Spain

17.9.2 Market Size of Glioblastoma Multiforme by Current Therapies

17.9.3 Market Size of Glioblastoma Multiforme by Emerging Therapies

17.1 United Kingdom

17.10.1 Total Market Size of Glioblastoma Multiforme in the United Kingdom

17.10.2 Market Size of Glioblastoma Multiforme by Current Therapies

17.10.3 Market Size of Glioblastoma Multiforme by Emerging Therapies

17.11 Japan: Market Outlook

17.11.1 Total Market Size of Glioblastoma Multiforme in Japan

17.11.2 Market Size of Glioblastoma Multiforme by Current Therapies

17.11.3 Market Size of Glioblastoma Multiforme by Emerging Therapies

18 Market Access and Reimbursement

18.1 United States

18.2 Europe

18.3 Japan

19 Case Reports

19.1 Glioblastoma and intracranial aneurysms: Case report and review of the literature (United States)

19.2 A New Method for Ethical and Efficient Evidence Generation for Off-label Medication Use in Oncology (A Case Study in Glioblastoma) (United Kingdom)

19.3 Diagnosis and treatment of early-stage glioblastoma (Japan)

20 KOL Reviews

21 Market Drivers

22 Market Barriers

23 SWOT Analysis

24 Appendix

24.1 Bibliography

24.2 Report Methodology

25 DelveInsight Capabilities

26 Disclaimer

27 About DelveInsight

List of Tables

Table 1: Summary of Glioblastoma Multiforme, Market, Epidemiology and Key Events (2017–2030)

Table 2: Total Diagnosed Incident Patient Population of Glioblastoma Multiforme in the 7MM (2017–2030)

Table 3: Total Diagnosed Incident Population of Glioblastoma Multiforme in the United States (2017–2030)

Table 4: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States (2017–2030)

Table 5: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States (2017–2030)

Table 6: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States (2017–2030)

Table 7: Diagnosed Incident Population based on Primary Site of GBM Tumor in the United States (2017–2030)

Table 8: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in the United States (2017–2030)

Table 9: Total Diagnosed Incident Population of Glioblastoma Multiforme in Germany (2017–2030)

Table 10: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017–2030)

Table 11: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017–2030)

Table 12: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017–2030)

Table 13: Diagnosed Incident Population based on Primary Site of Glioblastoma Multiforme Tumor in Germany (2017–2030)

Table 14: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in Germany (2017–2030)

Table 15: Total Diagnosed Incident Population of Glioblastoma Multiforme in France (2017–2030)

Table 16: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017–2030)

Table 17: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017–2030)

Table 18: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017–2030)

Table 19: Diagnosed Incident Population based on Primary Site of Glioblastoma Multiforme Tumor in France (2017–2030)

Table 20: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in France (2017–2030)

Table 21: Total Diagnosed Incident Population of Glioblastoma Multiforme in Italy (2017–2030)

Table 22: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017–2030)

Table 23: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017–2030)

Table 24: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017–2030)

Table 25: Diagnosed Incident Population based on Primary Site of Glioblastoma Multiforme Tumor in Italy (2017–2030)

Table 26: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in Italy (2017–2030)

Table 27: Total Diagnosed Incident Population of Glioblastoma Multiforme in Spain (2017–2030)

Table 28: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017–2030)

Table 29: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017–2030)

Table 30: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017–2030)

Table 31: Diagnosed Incident Population based on Primary Site of Glioblastoma Multiforme Tumor in Spain (2017–2030)

Table 32: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in Spain (2017–2030)

Table 33: Total Diagnosed Incident Population of Glioblastoma Multiforme in the United Kingdom (2017–2030)

Table 34: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom (2017–2030)

Table 35: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom (2017–2030)

Table 36: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom (2017–2030)

Table 37:Diagnosed Incident Population based on Primary Site of Glioblastoma Multiforme Tumor in the UK (2017–2030)

Table 38: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in the United Kingdom (2017–2030)

Table 39: Total Diagnosed Incident Population of Glioblastoma Multiforme in Japan (2017–2030)

Table 40: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017–2030)

Table 41: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017–2030)

Table 42: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017–2030)

Table 43: Diagnosed Incident Population based on Primary Site of GBM Tumor in Japan (2017–2030)

Table 44: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in Japan (2017–2030)

Table 45: Adjuvant Treatment of Glioblastoma based on Age and Karnofsky Performance Status

Table 46: Summary of recommendations

Table 47: Comparison of emerging drugs under development

Table 48: Comparison of emerging drugs under development

Table 49: VB-111, Clinical Trial Description, 2020

Table 50: Trans Sodium Crocetinate, Clinical Trial Description, 2020

Table 51: Regorafenib, Clinical Trial Description, 2020

Table 52: Durvalumab, Clinical Trial Description, 2020

Table 53: Tasadenoturev (DNX-2401), Clinical Trial Description, 2020

Table 54: ONC201, Clinical Trial Description, 2020

Table 55: Selinexor (KPT-330), Clinical Trial Description, 2020

Table 56: VBI-1901, Clinical Trial Description, 2020

Table 57: Paxalisib (GDC-0084), Clinical Trial Description, 2020

Table 58: AV-GBM-1, Clinical Trial Description, 2020

Table 59: MDNA55, Clinical Trial Description, 2020

Table 60: VAL-083 (Dianhydrogalactitol), Clinical Trial Description, 2020

Table 61: pp65 DC Vaccine, Clinical Trial Description, 2020

Table 62: INO-5401+ INO-9012+ Cemiplimab (REGN2810), Clinical Trial Description, 2020

Table 63: Total 7 Major Market Size of Glioblastoma Multiforme in USD Million (2017–2030)

Table 64: Total Market Size of Glioblastoma Multiforme in the United States, in USD Million (2017–2030)

Table 65: Market size of Glioblastoma Multiforme by Current Therapies in the United States, in USD Million (2017–2030)

Table 66: Market size of Glioblastoma Multiforme by Emerging Therapies in the United States, in USD Million (2017–2030)

Table 67: Total Market Size of Glioblastoma Multiforme in Germany, in USD Million (2017–2030)

Table 68: Market size of Glioblastoma Multiforme by Current Therapies in Germany, in USD Million (2017–2030)

Table 69: Market size of Glioblastoma Multiforme by Emerging Therapies in Germany, in USD Million (2017–2030)

Table 70: Total Market Size of Glioblastoma Multiforme in France, in USD Million (2017–2030)

Table 71: Market size of Glioblastoma Multiforme by Current Therapies in France, in USD Million (2017–2030)

Table 72: Market size of Glioblastoma Multiforme by Emerging Therapies in France, in USD Million (2017–2030)

Table 73: Total Market Size of Glioblastoma Multiforme in Italy, in USD Million (2017–2030)

Table 74: Market size of Glioblastoma Multiforme by Current Therapies in Italy, in USD Million (2017–2030)

Table 75: Market size of Glioblastoma Multiforme by Emerging Therapies in Italy, in USD Million (2017–2030)

Table 76: Total Market Size of Glioblastoma Multiforme in Spain, in USD Million (2017–2030)

Table 77: Market size of Glioblastoma Multiforme by Current Therapies in Spain, in USD Million (2017–2030)

Table 78: Market size of Glioblastoma Multiforme by Emerging Therapies in Spain, in USD Million (2017–2030)

Table 79: Total Market Size of Glioblastoma Multiforme in the United Kingdom, in USD Million (2017–2030)

Table 80: Market size of Glioblastoma Multiforme by Current Therapies in the United Kingdom, in USD Million (2017–2030)

Table 81: Market size of Glioblastoma Multiforme by Emerging Therapies in the UK, in USD Million (2017–2030)

Table 82: Total Market Size of Glioblastoma Multiforme in Japan, in USD Million (2017–2030)

Table 83: Market size of Glioblastoma Multiforme by Current Therapies in Japan, in USD Million (2017–2030)

Table 84:Market size of Glioblastoma Multiforme by Emerging Therapies in Japan, in USD Million (2017–2030)

List of Figures

Figure 1: Classification of Glioblastoma

Figure 2: Different types of Glioblastoma

Figure 3: Generalized transcription pathways related to Glioblastoma disease

Figure 4: Up-regulated Genetic Pathways in Glioblastoma

Figure 5: Overall pathways of IDH mutations

Figure 6: Chemistry of O6-Methylguanine-DNA Methyltransferase (MGMT)

Figure 7: Functioning of MicroRNA as a biomarker in Glioblastoma

Figure 8: Total Diagnosed Incident Patient Population of GBM in the 7MM (2017–2030)

Figure 9: Total Diagnosed Incident Population of Glioblastoma Multiforme in the US (2017–2030)

Figure 10: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the US (2017–2030)

Figure 11: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the US (2017–2030)

Figure 12: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the US (2017–2030)

Figure 13: Diagnosed Incident Population based on Primary Site of GBM Tumor in the US (2017–2030)

Figure 14: Diagnosed Incidence based on Histologic Classification of GBM Tumor in the US (2017–2030)

Figure 15: Total Diagnosed Incident Population of Glioblastoma Multiforme in Germany (2017–2030)

Figure 16: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017–2030)

Figure 17: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017–2030)

Figure 18: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017–2030)

Figure 19: Diagnosed Incident Population based on Primary Site of GBM Tumor in Germany (2017–2030)

Figure 20: Diagnosed Incidence based on Histologic Classification of GBM Tumor in Germany (2017–2030)

Figure 21: Total Diagnosed Incident Population of Glioblastoma Multiforme in France (2017–2030)

Figure 22: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017–2030)

Figure 23: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017–2030)

Figure 24: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017–2030)

Figure 25: Diagnosed Incident Population based on Primary Site of GBM Tumor in France (2017–2030)

Figure 26: Diagnosed Incidence based on Histologic Classification of GBM Tumor in France (2017–2030)

Figure 27: Total Diagnosed Incident Population of Glioblastoma Multiforme in Italy (2017–2030)

Figure 28: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017–2030)

Figure 29: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017–2030)

Figure 30: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017–2030)

Figure 31: Diagnosed Incident Population based on Primary Site of GBM Tumor in Italy (2017–2030)

Figure 32: Diagnosed Incidence based on Histologic Classification of GBM Tumor in Italy (2017–2030)

Figure 33: Total Diagnosed Incident Population of Glioblastoma Multiforme in Spain (2017–2030)

Figure 34: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017–2030)

Figure 35: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017–2030)

Figure 36: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017–2030)

Figure 37: Diagnosed Incident Population based on Primary Site of GBM Tumor in Spain (2017–2030)

Figure 38: Diagnosed Incidence based on Histologic Classification of GBM Tumor in Spain (2017–2030)

Figure 39: Total Diagnosed Incident Population of Glioblastoma Multiforme in the UK (2017–2030)

Figure 40: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the UK (2017–2030)

Figure 41: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the UK (2017–2030)

Figure 42: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the UK (2017–2030)

Figure 43: Diagnosed Incident Population based on Primary Site of GBM Tumor in the UK (2017–2030)

Figure 44: Diagnosed Incidence based on Histologic Classification of GBM Tumor in the UK (2017–2030)

Figure 45: Total Diagnosed Incident Population of Glioblastoma Multiforme in Japan (2017–2030)

Figure 46: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017–2030)

Figure 47: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017–2030)

Figure 48: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017–2030)

Figure 49: Diagnosed Incident Population based on Primary Site of GBM Tumor in Japan (2017–2030)

Figure 50: Diagnosed Incidence based on Histologic Classification of GBM Tumor in Japan (2017–2030)

Figure 51: NCCN Guidelines for treatment of Anaplastic Gliomas/Glioblastoma

Figure 52: NCCN Guidelines for Treatment of Recurrent Anaplastic Gliomas/Glioblastoma

Figure 53: Unmet Needs of Glioblastoma

Figure 54: Total 7 Major Market Size of Glioblastoma Multiforme in USD Million (2017–2030)

Figure 55: Total Market Size of GBM in the United States, USD Millions (2017–2030)

Figure 56: Market size of GBM by Current Therapies in the US, in USD Million (2017–2030)

Figure 57: Market size of GBM by Emerging Therapies in the US, in USD Million (2017–2030)

Figure 58: Total Market Size of Glioblastoma Multiforme in Germany, USD Million (2017–2030)

Figure 59: Market size of GBM by Current Therapies in Germany, in USD Million (2017–2030)

Figure 60: Market size of GBM by Emerging Therapies in Germany, in USD Million (2017–2030)

Figure 61: Total Market Size of Glioblastoma Multiforme in France, USD Million (2017–2030)

Figure 62: Market size of GBM by Current Therapies in France, in USD Million (2017–2030)

Figure 63: Market size of GBM by Emerging Therapies in France, in USD Million (2017–2030)

Figure 64: Total Market Size of Glioblastoma Multiforme in Italy, USD Million (2017–2030)

Figure 65: Market size of Glioblastoma Multiforme by Current Therapies in Italy, in USD Million (2017–2030)

Figure 66: Market size of GBM by Emerging Therapies in Italy, in USD Million (2017–2030)

Figure 67: Total Market Size of Glioblastoma Multiforme in Spain, USD Million (2017–2030)

Figure 68: Market size of Glioblastoma Multiforme by Current Therapies in Spain, in USD Million (2017–2030)

Figure 69: Market size of GBM by Emerging Therapies in Spain, in USD Million (2017–2030)

Figure 70: Total Market Size of GBM in the United Kingdom, USD Million (2017–2030)

Figure 71: Market size of GBM by Current Therapies in the UK, in USD Million (2017–2030)

Figure 72: Market size of GBM by Emerging Therapies in the UK, in USD Million (2017–2030)

Figure 73: Total Market Size of Glioblastoma Multiforme in Japan, USD Million (2017–2030)

Figure 74: Market size of Glioblastoma Multiforme by Current Therapies in Japan, in USD Million (2017–2030)

Figure 75: Market size of GBM by Emerging Therapies in Japan, in USD Million (2017–2030)

Figure 76: Market Drivers

Figure 77: Market Barriers

Figure 78: SWOT Analysis

Glioblastoma multiforme (GBM) market,Glioblastoma multiforme (GBM) market research,Glioblastoma multiforme (GBM) Companies,Glioblastoma multiforme (GBM) market trends,Glioblastoma multiforme (GBM) market forecast,Glioblastoma multiforme (GBM) market share,Glioblastoma multiforme (GBM) pipeline,Glioblastoma multiforme (GBM) treatment algorithm,Glioblastoma multiforme (GBM) drugs,Glioblastoma multiforme (GBM) sales forecasting,Glioblastoma multiforme (GBM) market size,Glioblastoma multiforme (GBM) disease,Glioblastoma multiforme (GBM) epidemiology,Glioblastoma multiforme (GBM)

  • Tags:
  • Glioblastoma multiforme (GBM) marke...
  • Glioblastoma multiforme (GBM) marke...
  • Glioblastoma multiforme (GBM) marke...
  • Glioblastoma multiforme (GBM) marke...
  • Glioblastoma multiforme (GBM) marke...
  • Glioblastoma multiforme (GBM)

Forward to Friend

Need A Quote